Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
138.41B
Market cap138.41B
Price-Earnings ratio
18.62
Price-Earnings ratio18.62
Dividend yield
7.08%
Dividend yield7.08%
Average volume
57.45M
Average volume57.45M
High today
$24.35
High today$24.35
Low today
$23.70
Low today$23.70
Open price
$23.74
Open price$23.74
Volume
59.96M
Volume59.96M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$23.11
52 Week low$23.11

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $24.27. The company's market cap stands at 138.41B, with a P/E ratio of 18.62 and a dividend yield of 7.08%.

On 2026-06-27, Pfizer(PFE) stock moved within a range of $23.70 to $24.35. With shares now at $24.27, the stock is trading +2.4% above its intraday low and -0.3% below the session's peak.

Trading activity shows a volume of 59.96M, compared to an average daily volume of 57.45M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $23.11.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $23.11.

PFE News

Nasdaq 51m
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now

Key Points Pfizer is one of the world's largest drug companies. It has a long history of navigating the industry's ups and downs. Pfizer is struggling today,...

Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now
The Motley Fool 5h
Here's How Many Shares of Pfizer You Must Own to Get $5,000 in Yearly Dividends

Looking for stocks that pay dividends? You may have come across pharmaceutical outfit Pfizer (PFE +2.62%) in your search. After all, its forward-looking dividen...

Here's How Many Shares of Pfizer You Must Own to Get $5,000 in Yearly Dividends
TipRanks 5h
Pfizer Balances Analyst Caution, Trial Shifts and CFO Exit

Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Unlock powerful investing tools and data-driven ins...

Analyst ratings

59%

of 29 ratings
Buy
34.5%
Hold
58.6%
Sell
6.9%

More PFE News

Simply Wall St 8h
Pfizer Wins EU Approval For Keytruda And Padcev In Bladder Cancer

Pfizer (NYSE:PFE) and Merck received European Commission approval for the Keytruda plus Padcev regimen in perioperative bladder cancer. The decision covers pat...

Pfizer Wins EU Approval For Keytruda And Padcev In Bladder Cancer
TipRanks 1d
Pfizer Halts Tafamidis Bioequivalence Study: What It Means for PFE Investors

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more c...

Nasdaq 2d
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?

Key Points AbbVie is aggressively expanding its pipeline to offset the impact of biosimilar competition for its top-selling drugs. Pfizer is utilizing substan...

AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
Benzinga 2d
FDA Expands Pfizer's Ibrance Label For Frontline Maintenance In Advanced Breast Cancer

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s (NYSE:PFE) Ibrance (palbociclib) regimen for frontline maintenance for metastat...

FDA Expands Pfizer's Ibrance Label For Frontline Maintenance In Advanced Breast Cancer
TipRanks 3d
Pfizer confirms FDA approval of Ibrance for HR+ metastatic breast cancer

Pfizer (PFE) announced the U.S. Food and Drug Administration approved Ibrance in combination with trastuzumab, with or without pertuzumab, and endocrine therapy...

Seeking Alpha 3d
Pfizer granted FDA label expansion for breast cancer drug, Ibrance

The U.S. Food and Drug Administration on Wednesday approved a label expansion for Pfizer’s (PFE) breast cancer therapy, palbociclib, marketed as Ibrance. Accor...

Pfizer granted FDA label expansion for breast cancer drug, Ibrance
TipRanks 3d
Pfizer Advances New Pediatric Pneumococcal “Catch-Up” Vaccine in Phase 3 Trial

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more c...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.